Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Return on Sales (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Return on Sales for 16 consecutive years, with 0.08% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Sales rose 35.0% to 0.08% in Q3 2025 year-over-year; TTM through Sep 2025 was 3.57%, a 385.0% increase, with the full-year FY2024 number at 0.01%, up 36.0% from a year prior.
  • Return on Sales was 0.08% for Q3 2025 at NovaBay Pharmaceuticals, down from 4.61% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 4.61% in Q2 2025 to a low of 1.33% in Q4 2023.
  • A 5-year average of 0.08% and a median of 0.12% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: crashed -199bps in 2023, then surged 443bps in 2025.
  • NovaBay Pharmaceuticals' Return on Sales stood at 0.04% in 2021, then skyrocketed by 1946bps to 0.66% in 2022, then plummeted by -302bps to 1.33% in 2023, then soared by 69bps to 0.42% in 2024, then soared by 118bps to 0.08% in 2025.
  • Per Business Quant, the three most recent readings for NBY's Return on Sales are 0.08% (Q3 2025), 4.61% (Q2 2025), and 2.02% (Q1 2025).